Patents by Inventor Sarah Spiegel

Sarah Spiegel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sphingosine kinase Type 1 inhibitors and uses thereof
    Patent number: 11737992
    Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in the treatment of neuropathic pain.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: August 29, 2023
    Assignees: ENZO THERAPEUTICS, INC., VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • SPHINGOSINE KINASE TYPE 1 INHIBITORS AND USES THEREOF
    Publication number: 20210177776
    Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in the treatment of neuropathic pain.
    Type: Application
    Filed: February 8, 2021
    Publication date: June 17, 2021
    Applicants: Enzo Therapeutics, Inc., Virginia Commonwealth University
    Inventors: Sarah SPIEGEL, Robert Elliot ZIPKIN, Jeffrey Kroll ADAMS
  • Sphingosine kinase type 1 inhibitors and uses thereof
    Patent number: 10945971
    Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating ischemic diseases such as myocardial infarction and stroke.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: March 16, 2021
    Assignees: Enzo Therapeutics, Inc., Virginia Commonwealth University
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • SPHINGOSINE KINASE TYPE 1 INHIBITORS AND USES THEREOF
    Publication number: 20200197328
    Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating ischemic diseases such as myocardial infarction and stroke.
    Type: Application
    Filed: March 10, 2020
    Publication date: June 25, 2020
    Applicants: Enzo Therapeutics, Inc., Virginia Commonwealth University
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • Sphingosine kinase type 1 inhibitors and uses thereof
    Patent number: 10624863
    Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: April 21, 2020
    Assignees: Enzo Therapeutics, Inc., Virginia Commonwealth University
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • SPHINGOSINE KINASE TYPE 1 INHIBITORS AND USES THEREOF
    Publication number: 20200069611
    Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).
    Type: Application
    Filed: September 17, 2019
    Publication date: March 5, 2020
    Applicants: Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc., Virginia Commonwealth University
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • Sphingosine kinase type 1 inhibitors and uses thereof
    Patent number: 10456370
    Abstract: Provided are inhibitors of sphingosine kinase Type I and their use in the treatment of asthma, among other indications and diseases.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: October 29, 2019
    Assignees: Enzo Therapeutics, Inc., Virginia Commonwealth University
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • SPHINGOSINE KINASE TYPE 1 INHIBITORS AND USES THEREOF
    Publication number: 20190111007
    Abstract: Provided are inhibitors of sphingosine kinase Type I and their use in the treatment of asthma, among other indications and diseases.
    Type: Application
    Filed: November 26, 2018
    Publication date: April 18, 2019
    Applicants: Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc., Virginia Commonwealth University
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • Sphingosine kinase type 1 inhibitors and uses thereof
    Patent number: 10166204
    Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: January 1, 2019
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • SPHINGOSINE KINASE TYPE 1 INHIBITORS AND USES THEREOF
    Publication number: 20180235907
    Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).
    Type: Application
    Filed: April 16, 2018
    Publication date: August 23, 2018
    Applicants: Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc., Virginia Commonwealth University
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • Sphingosine kinase type 1 inhibitors and uses thereof
    Patent number: 9974758
    Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: May 22, 2018
    Assignees: Enzo Therapeutics, Inc., Virginia Commonwealth University
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • 3-(2-amino-ethyl)-alkylidene)-thiazolidine-2,4-dione and 1-(2-amino-ethyl)-alkylidene-1,3-dihydro-indol-2-one derivatives as selective sphingosine kinase 2 inhibitors
    Patent number: 9598384
    Abstract: 3-(2-amino-ethyl)-5-[3-(4-substituted-phenyl)-alkylidene)-thiazolidine-2,4-dione and 1-(2-amino-ethyl)-3-alkylidene-1,3-dihydro-indol-2-one and derivatives thereof are provided for use as selective SphK2 inhibitors and for use in the treatment of human diseases, such as cancer.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: March 21, 2017
    Assignee: Virginia Commonwealth University
    Inventors: Shijun Zhang, Sarah Spiegel
  • Sphingosine Kinase Type 1 Inhibitors and Uses Thereof
    Publication number: 20160317472
    Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).
    Type: Application
    Filed: June 14, 2016
    Publication date: November 3, 2016
    Applicants: Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc., Virginia Commonwealth University
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • Sphingosine kinase type 1 inhibitors
    Patent number: 9388121
    Abstract: Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: July 12, 2016
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • 3-(2-AMINO-ETHYL)-ALKYLIDENE)-THIAZOLIDINE-2,4-DIONE AND 1-(2-AMINO-ETHYL)-ALKYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS SELECTIVE SPHINGOSINE KINASE 2 INHIBITORS
    Publication number: 20160159758
    Abstract: 3-(2-amino-ethyl)-5-[3-(4-substituted-phenyl)-alkylidene)-thiazolidine-2,4-dione and 1-(2-amino-ethyl)-3-alkylidene-1,3-dihydro-indol-2-one and derivatives thereof are provided for use as selective SphK2 inhibitors and for use in the treatment of human diseases, such as cancer.
    Type: Application
    Filed: November 5, 2015
    Publication date: June 9, 2016
    Inventors: Shijun ZHANG, Sarah SPIEGEL
  • 3-(2-AMINO-ETHYL)-ALKYLIDENE)-THIAZOLIDINE-2,4-DIONE AND 1-(2-AMINO-ETHYL)-ALKYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS SELECTIVE SPHINGOSINE KINASE 2 INHIBITORS
    Publication number: 20150005353
    Abstract: 3-(2-amino-ethyl)-5-[3-(4-substituted-phenyl)-alkylidene)-thiazolidine-2,4-dione and 1-(2-amino-ethyl)-3-alkylidene-1,3-dihydro-indol-2-one and derivatives thereof are provided for use as selective SphK2 inhibitors and for use in the treatment of human diseases, such as cancer.
    Type: Application
    Filed: February 7, 2013
    Publication date: January 1, 2015
    Applicant: Virginia Commonwealth University
    Inventors: Shijun Zhang, Sarah Spiegel
  • SPHINGOSINE KINASE TYPE 1 INHIBITORS
    Publication number: 20130245321
    Abstract: Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).
    Type: Application
    Filed: October 11, 2012
    Publication date: September 19, 2013
    Inventors: SARAH SPIEGEL, ROBERT ELLIOT ZIPKIN, JEFFREY KROLL ADAMS
  • Sphingosine kinase type 1 inhibitors, compositions and processes for using same
    Patent number: 8372888
    Abstract: Provided are novel compositions which uniquely inhibit sphingosine kinase Type 1 (SphK1) and which are useful in a number of applications including killing or damaging cancer cells, inducing apoptosis, inhibiting growth, metastasis and development of chemoresistance in cancer cells, leukemia, increasing the effectiveness of anti-cancer agents, attenuating immune reactivity, inhibiting survival signaling in cancer cells, and reducing symptoms of multiple sclerosis.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: February 12, 2013
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Robert E. Zipkin, Sarah Spiegel, Jeffrey Kroll Adams
  • Sphingosine kinase type 1 inhibitors, and processes for using same
    Patent number: 8314151
    Abstract: Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: November 20, 2012
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • SPHINGOSINE KINASE TYPE 1 INHIBITORS, AND PROCESSES FOR USING SAME
    Publication number: 20120237448
    Abstract: Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).
    Type: Application
    Filed: August 31, 2009
    Publication date: September 20, 2012
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams